An Arkansas judge said Johnson & Johnson and unit Janssen Pharmaceuticals must pay $1.2 billion for violating the state's False Claims and Deceptive Trade Practices acts in regard to marketing antipsychotic Risperdal. The penalty signals that big drugmakers "cannot lie to the FDA, patients and doctors in order to defraud Arkansas taxpayers of our Medicaid dollars," Arkansas Attorney General Dustin McDaniel said. A spokeswoman for Janssen said evidence showed the firms acted legally, and they will appeal.

Full Story:

Related Summaries